SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gabe Fernandez who wrote (977)1/26/2000 1:29:00 PM
From: NeuroInvestment  Read Replies (3) of 1386
 
You are preaching to the choir. If you read my post carefully, it discusses the FDA's resistance to accepting ICP as a primary endpoint--they want functional outcome measures, showing that the variety of mechanisms presumed for HU211 affect patient functioning (cognitive, occupational, self-care,etc). You and I can agree that reducing ICP leads to an expected sequence of desirable events, and is thus a worthwhile endpoint in itself. But the FDA apparently does not agree.

NeuroInvestment (www.neuroinvestment.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News